Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tavo-EP, Pembrolizumab, and Epacadostat in HNSCC
NCT03823131Phase 2Terminated
- Start
- May 2019
- Primary completion
- Jul 2022
- Modality
- Gene Editing, Gene Silencing, Gene Addition/Replacement
- Countries
- 1
01
Overview
Phase 2, open-label trial of tavokinogene telseplasmid in head and neck squamous cell carcinoma (HNSCC). Started May 2019; status: terminated.
02
Drugs
tavokinogene telseplasmid
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT03823131.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03823131.